Article

Use of an integrated pan-cancer oncology enrichment NGS assay to measure tumour mutational burden and detect clinically actionable variants

2020-02-04

Abstract excerpt

<h4>Introduction</h4> The identification of tumour mutational burden (TMB) as a biomarker of response to PD-1 immunotherapy has necessitated the development of genomic assays to measure this. We carried out comprehensive molecular profiling of cancers using the Illumina TruSight Oncology panel (TSO500) and compared to whole genome sequencing. <h4>Methods</h4> Cancer samples derived from formalin fixed material wer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7b13381c-69f5-5e53-97ea-dc62ad7fb5f7
DOI: 10.1101/2020.02.01.20019992

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Use of an integrated pan-cancer oncology enrichment NGS assay to measure tumour mutational burden and detect clinically actionable variantsDOI 10.1101/2020.02.01.20019992Read

Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.Semantic proximity Read

TruSight Oncology 500: Enabling Comprehensive Genomic Profiling and Biomarker Reporting with Targeted SequencingSemantic proximity Read

Validation of a targeted sequencing panel with automatic analysis system for clinical decision support in cancer therapySemantic proximity Read

Target-enhanced whole-genome sequencing (TE-WGS) shows clinical validity equivalent to commercially available targeted oncology panelSemantic proximity Read

Clinical and Technical Validation of OncoIndx® Assay – A Comprehensive Genome Profiling Assay for Pan-Cancer InvestigationsSemantic proximity Read

Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid TumorsSemantic proximity Read

Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centreSemantic proximity Read

Utilizing Targeted Enhanced-Whole-Genome Sequencing in Precision Oncology for the Treatment of Solid Tumors: A Clinical PerspectiveSemantic proximity Read

Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.Semantic proximity Read

Effective quality management practices in routine clinical next-generation sequencingSemantic proximity Read

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.Semantic proximity Read

An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testingSemantic proximity Read